SCHEMBL6318521

SCHEMBL6318521

CNCCOc1ccccc1C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 3/20 0.73
HTR1D P28221 2/20 0.61
DRD2 P14416 2/20 0.60
DRD4 P21917 2/20 0.60
HRH1 P35367 3/20 0.57
DRD3 P35462 2/20 0.57
SLC6A4 P31645 2/20 0.54
ALDH1A1 P00352 5/20 0.54
CYP1A2 P05177 4/20 0.54
CYP3A4 P08684 4/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 5/20 0.53
LMNA P02545 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KMT2A Q03164 2/20 0.53
HPGD P15428 1/20 0.53
TP53 P04637 2/20 0.51
TSHR P16473 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633202 0.94 HTR1B (0.66) HTR1BHTR1DDRD2DRD4HRH1
Hydrochloric Acid SCHEMBL6071440 0.92 HTR1B (0.64) HTR1BHTR1DDRD2DRD4HRH1
SCHEMBL7908960 0.87 HTR1B (0.69) HTR1BHTR1DHRH1SLC6A4ALDH1A1
SCHEMBL23067912 0.86 DRD2 (0.77) HTR1BDRD2DRD4DRD3ALDH1A1
SCHEMBL10993201 0.84 HTR1B (0.58) HTR1BHTR1DDRD2DRD4HRH1
SCHEMBL1592876 0.83 TDP1 (0.60) DRD2DRD4DRD3ALDH1A1CYP1A2
SCHEMBL11348527 0.81 DRD2 (0.66) HTR1BDRD2DRD4DRD3ALDH1A1
SCHEMBL11679951 0.81 CYP2D6 (0.61) DRD2DRD4DRD3ALDH1A1CYP1A2
SCHEMBL9808080 0.81 ALDH1A1 (0.62) DRD2DRD4DRD3ALDH1A1CYP1A2
SCHEMBL6192822 0.80 MTNR1A (0.62) HTR1BHTR1DHRH1SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210069692-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS BIO-RAD LABORATORIES, INC. 2021-03-11 US disclosed
US-9822115-B2 Nitrogen containing compounds and their use as antibacterial agents WOCKHARDT LIMITED (IN) 2017-11-21 US disclosed
US-20160355516-A1 NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS WOCKHARDT LIMITED (IN) 2016-12-08 US disclosed
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP disclosed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO disclosed
EP-1037871-B1 NOVEL ANTIARRHYTHMIC COMPOUNDS GYOGYSZERKUTATO INTEZET (HU) 2002-07-03 EP disclosed
US-6265445-B1 CARDIOVASCULAR DISORDERS GYOGYSZERKUTATO INTEZET KFT (HU) 2001-07-24 US disclosed
EP-1037871-A1 NOVEL ANTIARRHYTHMIC COMPOUNDS GYOGYSZERKUTATO INTEZET KFT. (HU) 2000-09-27 EP disclosed
WO-1999029655-A1 NOVEL ANTIARRHYTHMIC COMPOUNDS Gyógyszerkutató Intézet Kft. (HU) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069692-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885DRD2 2750/4885
US-20160355516-A1 NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS NOS2, NOS1, NCF1 HTR1B 3219/4885HTR1D 4117/4885DRD2 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.